Skip to content

For in vitro research use only. Not for human or animal consumption.

VaultLabs logo

Peptide encyclopedia · Metabolic research

Cagrilintide research summary

Long-acting amylin analogue · Full compound profile

Also see the expanded Cagrilintide compound database page with filters, related articles, and catalog links.

All VaultLabs products are supplied strictly for laboratory and research use only. They are not intended for human consumption, medical use, personal use, or diagnostic use.

Cagrilintide is a long-acting amylin analogue, a lipidated peptide distinct from GLP-1 receptor agonists. VaultLabs supplies it as standalone 5 mg and 10 mg lyophilized vials for in vitro laboratory work. It is not retatrutide, not the cagrilintide portion of the RETA/CAG blend, and not an approved medicine. In the VaultLabs catalogue this is Long-acting amylin analogue material for in vitro laboratory research, not a medicine and not a protocol.

What it is
Long-acting amylin analogue
Category
Metabolic research
CAS
1415456-99-3
Formula
C194H312N54O59S2
Catalogue price before VAT
5 mg at AED 449; 10 mg at AED 649

Identity on this record

Chemical name: Cagrilintide.

Common synonyms: Cagri, long-acting amylin analogue.

CAS number: 1415456-99-3 (registry entry).

Molecular formula: C194H312N54O59S2.

Molecular weight: 4409.07 g/mol.

Catalog strength: 5 mg and 10 mg vials.

Those identifiers describe Cagrilintide as a substance. They do not describe a particular vial. The vial is identified by the name, the nominal fill, and the lot number on its label, checked against the published certificate.

What the catalogue actually sells

Cagrilintide 5mg is the 5 mg lyophilized unit, listed at AED 449 before VAT. The product record stores that sealed unit at 2–8 °C · protect from light. Cagrilintide 10mg is the 10 mg lyophilized unit, listed at AED 649 before VAT. The product record stores that sealed unit at 2–8 °C · protect from light.

Prices are merchandise prices in AED, exclusive of VAT. VAT is added at checkout. A price on this summary is the figure on the product record for Cagrilintide, not a delivered-cost quote.

Lots and certificates

Lot VL-CAGR10-20261020 is the catalogue certificate for Cagrilintide 10mg. Read it on Cagrilintide 10mg certificate and match the vial in batch verification. A certificate for a different strength, or for a blend that merely contains the same name, does not release this unit.

Lot VL-CAGR5-20261020 is the catalogue certificate for Cagrilintide 5mg. Read it on Cagrilintide 5mg certificate and match the vial in batch verification. A certificate for a different strength, or for a blend that merely contains the same name, does not release this unit.

How the compound record describes the literature

Cagrilintide is the catalogue name for the long-acting amylin analogue with CAS 1415456-99-3. Public records describe a 38-residue peptide with a fatty diacid and a disulfide. That is a different molecule from retatrutide (CAS 2381089-83-2), which is the GLP-3 RT line. Ordering one when the protocol names the other is a receiving error, not a strength choice.

Topics named on the Cagrilintide record, as literature context rather than as outcomes VaultLabs claims: Amylin analogue, not a GLP-1, GIP or glucagon receptor agonist.; CAS 1415456-99-3. Formula C194H312N54O59S2. Molecular weight 4409.07 g/mol.; Catalogue fills are 5 mg and 10 mg. Each fill has its own lot.; RETA/CAG is a different product: retatrutide 12.5 mg plus cagrilintide 2.5 mg in one vial..

That is context for identifying Cagrilintide. It is not a claim that a vial produces a result in a person, an animal, or a study VaultLabs has not published. VaultLabs does not provide dosage, administration, study-design, or medical guidance.

Points the monograph already states

Points already written on the Cagrilintide monograph, so a reader can check them against that page:

Amylin analogue, not a GLP-1, GIP or glucagon receptor agonist.

CAS 1415456-99-3. Formula C194H312N54O59S2. Molecular weight 4409.07 g/mol.

Catalogue fills are 5 mg and 10 mg. Each fill has its own lot.

RETA/CAG is a different product: retatrutide 12.5 mg plus cagrilintide 2.5 mg in one vial.

Published clinical papers describe other sponsors' studies. They are not a description of this vial.

Supplied for laboratory research. Not for human use.

Dispatch and the research-use boundary

VaultLabs dispatches Cagrilintide from Dubai. Orders leave fulfillment within 24 hours, 7 days a week. Standard delivery is AED 35 to every emirate, and delivery is free when the post-discount merchandise subtotal is AED 500 or more. Checkout shows the fee for the address entered. All VaultLabs products are supplied strictly for laboratory and research use only. They are not intended for human consumption, medical use, personal use, or diagnostic use. VaultLabs does not provide dosage, administration, study-design, or medical guidance.

The full narrative record is the Cagrilintide compound monograph. Handling of the sealed unit is the Cagrilintide storage guide. Questions are collected on the Cagrilintide FAQ. How it differs from neighbouring records is the Cagrilintide comparison.

Questions this page answers

What is Cagrilintide on this site?

Cagrilintide is a long-acting amylin analogue, a lipidated peptide distinct from GLP-1 receptor agonists. VaultLabs supplies it as standalone 5 mg and 10 mg lyophilized vials for in vitro laboratory work. It is not retatrutide, not the cagrilintide portion of the RETA/CAG blend, and not an approved medicine. VaultLabs supplies it as in vitro research material. The monograph prints CAS 1415456-99-3.

Related compounds

Research tools

Catalog products

Next recommended reading

All VaultLabs products are supplied strictly for laboratory and research use only. They are not intended for human consumption, medical use, personal use, or diagnostic use.